Amidst the COVID-19 pandemic, there has been an evident surge in demand for standard quality antibodies for research, diagnosis and therapeutic purposes, which has presented lucrative opportunities for contract service providers having antibody purification capabilities
Isolation and purification of antibodies, from different sources, including serum, ascites fluid and hybridoma cell culture, requires specialized equipment and focused expertise; as a result, drug developers and academic institutions outsource various aspects of downstream processing, including antibody purification to contract service providers, that claim to have the required capabilities for purification of antibodies in minimum time with reduced chances of failure.
To order this 270+ page report, which features 100+ figures and 130+ tables, please visit
Key Market Insights
More than 150 players claim to offer services for purification of antibodies
The market is predominantly characterized by the presence of small firms (having less than 50 employees). It is worth noting that more than 75% of the players purify antibodies isolated from serum, followed by hybridoma cell culture supernatant (58%). Further, more than 30% players provide purification services for both monoclonal and polyclonal antibodies.
Over 80% antibody purification service providers are based in North America and Europe
Within North America, majority (91%) of the players are headquartered in the US, whereas in Europe, most of the companies are based in the UK (17), Germany (11), France (11) and Sweden (5).
Presently, more than 100 players use class-specific methods to isolate specific antibody isotypes
Most of the players use Protein A and Protein G resin, for affinity column chromatography. Of the players using physico-chemical antibody purification methods, majority (77%) employ ion exchange chromatography, followed by size exclusion chromatography.
The demand for purified antibodies is expected to grow to over 47,000 Kg, till 2025
Currently, North America is estimated to contribute to nearly 50% of the overall purification demand for clinical and commercial- grade therapeutic antibodies. By 2025, the global demand for approved / marketed antibodies is estimated to grow to over 42,000 Kg, primarily driven by the anticipated growth in the sales of monoclonal antibody products.
Start- ups / small firms are expected to capture nearly 40% share of the market share by 2030
With regard to the regional distribution, Europe is anticipated to contribute to more than 70% of the total service revenues generated in 2030. In the long term, physico-chemical purification is likely to become the preferred choice for antibody purification service providers; projects involving the aforementioned technique are expected to capture majority share (40%) of the total market.
To request a sample copy / brochure of this report, please visit
Key Questions Answered
The USD 2 billion (by 2030) financial opportunity within the antibody purification services market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom, in the foreseen future, competition within antibody purification services market is expected to grow significantly, resulting in an increase in the overall market value. The report includes detailed transcript of discussion held with Colby Sounders (Chief Scientific Officer, Abveris).
The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), a description of the antibody purification service(s) offered, details of recent developments along with an informed future outlook.
For additional details, please visit
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091